Brief: Adial Pharma Receives Positive Response From FDA Meeting Regarding Vitro Bridging Strategy For AD04
25/02/2025 14:43
Feb 25 (Reuters) - Adial Pharmaceuticals Inc ADIL.O: ADIAL PHARMACEUTICALS RECEIVES POSITIVE RESPONSE FROM FDA MEETING REGARDING PROPOSED IN VITRO BRIDGING STRATEGY FOR AD04 ADIAL PHARMACEUTICALS- MOVES FORWARD WITH MANUFACTURING CLINICAL SUPPLIES FOR PHASE 3 PROGRAM IN 2025 Source text: ID:nGNX9ZpY9Q Further company coverage: ADIL.O ((Reuters.Briefs@thomsonreuters.com;))